NRx Pharmaceuticals to Report Q3 2025 Financial Results and Provide Corporate Updates

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, will release its third quarter 2025 financial results before market open on Monday, November 17, 2025. The company will follow the earnings release with a conference call at 8:30 a.m. ET to discuss corporate, financial, and operational updates. This quarterly reporting provides investors and stakeholders with critical insights into the company's financial health and progress in developing treatments for central nervous system disorders.

The timing of this financial disclosure is particularly significant given NRx Pharmaceuticals' ongoing clinical development programs. The company specializes in therapeutics based on its NMDA platform targeting serious conditions including suicidal depression, chronic pain, and PTSD. Investors will be watching closely for updates on the company's two lead candidates: NRX-100, a preservative-free intravenous ketamine, and NRX-101, an oral combination of D-cycloserine and lurasidone.

NRx Pharmaceuticals has achieved important regulatory milestones that could substantially impact its valuation and future prospects. NRX-100 has received Fast Track Designation from the FDA for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. Meanwhile, NRX-101 has been granted Breakthrough Therapy Designation for suicidal bipolar depression. These designations can accelerate the development and review process for promising therapies addressing unmet medical needs.

The company recently filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner's National Priority Voucher Program for the treatment of suicidal depression. This regulatory progress represents a critical step toward potential commercialization of treatments for conditions that currently lack effective therapeutic options. Additional information about the company's developments is available in their newsroom at https://ibn.fm/NRXP.

For the broader biopharmaceutical industry, NRx Pharmaceuticals' progress highlights the growing focus on novel approaches to treating central nervous system disorders. The company's NMDA platform represents an innovative mechanism of action that could offer new hope for patients with treatment-resistant conditions. The upcoming financial results and operational updates will provide important indicators of the company's ability to advance these promising therapies through clinical development and toward regulatory approval.

The conference call following the earnings release will offer management the opportunity to detail progress across their development pipeline and provide context for the financial results. Stakeholders will be particularly interested in updates regarding the regulatory timeline for NRX-100 and NRX-101, as well as any new clinical data or partnership announcements. The full press release containing additional details about the upcoming earnings announcement can be accessed at https://ibn.fm/RNyEd.